Related Experiment Videos
Primary progressive multiple sclerosis: a distinct syndrome?
1Royal Victoria Hospital, Belfast, Northern Ireland.
Abstract:
Multiple sclerosis (MS) has long been recognised to have both a relapsing-remitting and progressive course. More recently patients with progressive disease have been further sub-divided into those with a progressive course from onset (primary progressive MS) and those with progressive decline following an initially relapsing-remitting period (secondary progressive MS). Diversity in MS may not however be restricted to clinical course. There is growing evidence that the subgroups of MS also differ with respect to clinical features, epidemiology, pathogenesis, genetics and neuroimaging appearances. In this review we outline the criteria variously applied in the classification of MS patients, addressing the need for a clear nomenclature. We evaluate the proposition that primary progressive MS has a profile distinct from other MS categories, contrasting the separate differential diagnoses and examining the implications for future therapeutic trials.
Insights
Multiple sclerosis (MS) presents diverse clinical courses, including relapsing-remitting and progressive forms. This review explores distinct profiles of primary progressive MS versus other subtypes, impacting diagnosis and treatment trials.
Area of Science:
- Neurology
- Immunology
- Clinical Medicine
Background:
- Multiple sclerosis (MS) is recognized for relapsing-remitting and progressive clinical courses.
- Progressive MS is further classified into primary progressive MS (PPMS) and secondary progressive MS (SPMS).
- Emerging evidence suggests distinct differences among MS subtypes in clinical, epidemiological, and pathological aspects.
Purpose of the Study:
- To review current criteria for classifying MS patients and highlight the need for standardized nomenclature.
- To evaluate whether primary progressive MS (PPMS) exhibits a unique profile compared to other MS categories.
- To examine the implications of MS subtype diversity for differential diagnoses and future therapeutic trials.
Main Methods:
- Literature review of existing classification criteria for multiple sclerosis.
- Comparative analysis of clinical features, epidemiology, pathogenesis, genetics, and neuroimaging across MS subtypes.
- Evaluation of diagnostic criteria and therapeutic trial designs in the context of MS heterogeneity.
Main Results:
- MS exhibits significant diversity beyond clinical course, with potential differences in clinical presentation, epidemiology, pathogenesis, genetics, and neuroimaging.
- Primary progressive MS (PPMS) may represent a distinct entity with unique characteristics.
- Current classification systems and nomenclature for MS subtypes require refinement.
Conclusions:
- Recognizing the distinct profiles of MS subtypes, particularly PPMS, is crucial for accurate diagnosis and effective treatment.
- Further research is needed to elucidate the specific differences between MS subtypes.
- A clear and consistent nomenclature is essential for advancing MS research and clinical management, especially for therapeutic trials.